BHCM
PLX icon

Brevan Howard Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Brevan Howard Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,474
Closed -$34.5K – 1973
2025
Q1 		$34.5K Buy
+13,474
New +$32.2K ﹤0.01% 1102

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Brevan Howard Capital Management's PLX Position: Q2 2025 in Review

Brevan Howard Capital Management sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 13,474 shares — an estimated $34.5K sold.

Brevan Howard Capital Management first reported a position in PLX in Q1 2025 and held it in 1 quarter. The position peaked at $34.5K in Q1 2025. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

  • Brevan Howard Capital Management reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 13,474 Protalix BioTherapeutics shares in Q2 2025, an estimated $34.5K.
  • Brevan Howard Capital Management first reported a position in Protalix BioTherapeutics in Q1 2025 and held it in 1 quarter.
  • Brevan Howard Capital Management's Protalix BioTherapeutics position peaked at $34.5K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on Brevan Howard Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.